Portolan Capital Management’s Abiomed Inc ABMD Stock Holding History

Portolan Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,139	Closed	-$1.75M	–	165
2022 Q3	$1.75M	Sell	7,139 -15	-0.2%	-$4.05K	0.19%	114
2022 Q2	$1.77M	Hold	7,154	–	–	0.18%	115
2022 Q1	$2.37M	Buy	7,154 +69	+1%	+$21.2K	0.19%	118
2021 Q4	$2.54M	Buy	7,085 +15	+0.2%	+$5.07K	0.17%	110
2021 Q3	$2.3M	Sell	7,070 -63	-0.9%	-$21.3K	0.17%	115
2021 Q2	$2.23M	Sell	7,133 -82	-1%	-$25.2K	0.16%	109
2021 Q1	$2.3M	Sell	7,215 -22	-0.3%	-$7.04K	0.18%	125
2020 Q4	$2.35M	Sell	7,237 -440	-6%	-$122K	0.21%	125
2020 Q3	$2.13M	Sell	7,677 -708	-8%	-$204K	0.24%	108
2020 Q2	$2.02M	Sell	8,385 -3,770	-31%	-$757K	0.23%	110
2020 Q1	$1.76M	Sell	12,155 -13,105	-52%	-$2.18M	0.26%	92
2019 Q4	$4.31M	Buy	25,260 +21,632	+596%	+$4.01M	0.44%	70
2019 Q3	$645K	Buy	3,628 +44	+1%	+$9.51K	0.07%	84
2019 Q2	$934K	Buy	3,584 +103	+3%	+$27.3K	0.1%	82
2019 Q1	$994K	Hold	3,481	–	–	0.1%	84
2018 Q4	$1.13M	Sell	3,481 -199	-5%	-$69.1K	0.14%	77
2018 Q3	$1.66M	Sell	3,680 -1,020	-22%	-$402K	0.16%	84
2018 Q2	$1.92M	Sell	4,700 -2,499	-35%	-$905K	0.2%	82
2018 Q1	$2.1M	Sell	7,199 -15,241	-68%	-$3.86M	0.23%	85
2017 Q4	$4.21M	Sell	22,440 -23,814	-51%	-$4.45M	0.46%	78
2017 Q3	$7.8M	Sell	46,254 -14,422	-24%	-$2.18M	0.93%	40
2017 Q2	$8.7M	Sell	60,676 -21,622	-26%	-$2.91M	1.12%	29
2017 Q1	$10.3M	Buy	82,298 +30,842	+60%	+$3.58M	1.34%	19
2016 Q4	$5.8M	Buy	51,456 +20,568	+67%	+$2.38M	0.78%	50
2016 Q3	$3.97M	Sell	30,888 -16,832	-35%	-$2.02M	0.55%	64
2016 Q2	$5.21M	Sell	47,720 -28,830	-38%	-$2.87M	0.75%	51
2016 Q1	$7.26M	Sell	76,550 -2,560	-3%	-$216K	0.97%	36
2015 Q4	$7.14M	Sell	79,110 -24,028	-23%	-$2.04M	0.91%	35
2015 Q3	$9.57M	Sell	103,138 -164,802	-62%	-$14.5M	1.27%	20
2015 Q2	$17.6M	Buy	267,940 +49,292	+23%	+$3.27M	2.46%	5
2015 Q1	$15.7M	Sell	218,648 -64,859	-23%	-$3.52M	2.87%	1
2014 Q4	$10.8M	Sell	283,507 -125,704	-31%	-$3.96M	2.16%	7
2014 Q3	$10.2M	Buy	409,211 +72,434	+22%	+$1.83M	2.31%	3
2014 Q2	$8.47M	Buy	336,777 +142,155	+73%	+$3.31M	1.85%	8
2014 Q1	$5.07M	Sell	194,622 -12,208	-6%	-$338K	1.17%	27
2013 Q4	$5.53M	Sell	206,830 -110,324	-35%	-$2.73M	1.23%	25
2013 Q3	$6.04M	Sell	317,154 -65,785	-17%	-$1.5M	1.58%	19
2013 Q2	$8.26M	Buy	+382,939	New	+$7.7M	2.35%	5

Other funds holding ABMD

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Avion Wealth The Woodlands, Texas $484M AUM 15.17% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Portolan Capital Management's ABMD Position: Q4 2022 in Review

Portolan Capital Management sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 7,139 shares — an estimated $1.75M sold.

Portolan Capital Management first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $17.6M in Q2 2015. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

Portolan Capital Management reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
Portolan Capital Management sold 7,139 Abiomed Inc shares in Q4 2022, an estimated $1.75M.
Portolan Capital Management first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
Portolan Capital Management's Abiomed Inc position peaked at $17.6M in Q2 2015.
8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Portolan Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.